Changes in Metabolic Status in Patients With Total Thyroidectomy (Thyroid cancer)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nachum Vaisman, M.D.
- Phone Number: 972-3-6974807
- Email: vaisman@tasmc.health.gov.il
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Recruiting
- Tel Aviv Sourasky Medical Center
-
Contact:
- Nachum Vaisman, M.D.
- Phone Number: 972-3-6974807
- Email: vaisman@tasmc.health.gov.il
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who were diagnosed with thyroid carcinoma and are going to have total thyroidectomy.
- Patients with unbalanced thyroid hormones.
- Aged 18-65 years at the time of screening.
- Provision of written informed consent.
Exclusion Criteria:
- Patients with Diabetes.
- Patients with any other chronic inflammatory diseases.
- Steroid treatment.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in UCP2 mRNA concentrations.
Time Frame: Base line (before opporation), 2 weeks after opporation and for after opporation.
|
The difference between the result at two weeks and four months compare to base line.
|
Base line (before opporation), 2 weeks after opporation and for after opporation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Weight
Time Frame: Approximately 4 months
|
Approximately 4 months
|
|
Resting energy expenditure
Time Frame: Approximatly 4 months
|
Approximatly 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001 Jul;81(3):1097-142. doi: 10.1152/physrev.2001.81.3.1097.
- Schwartz HL, Oppenheimer JH. Physiologic and biochemical actions of thyroid hormone. Pharmacol Ther B. 1978;3(3):349-76. doi: 10.1016/s0306-039x(78)80002-6. No abstract available.
- Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005 Aug;2(2):85-93. doi: 10.1016/j.cmet.2005.06.002.
- Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev. 1984 Jan;64(1):1-64. doi: 10.1152/physrev.1984.64.1.1. No abstract available.
- Gjedde S, Gormsen LC, Riis AL, Jorgensen JO, Rungby J, Moller N, Weeke J, Pedersen SB. Reduced expression of uncoupling protein 2 in adipose tissue in patients with hypothyroidism. J Clin Endocrinol Metab. 2010 Jul;95(7):3537-41. doi: 10.1210/jc.2009-0907. Epub 2010 Apr 28.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TASMC-12-NV-376-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.